GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » EV-to-FCF

Nymox Pharmaceutical (Nymox Pharmaceutical) EV-to-FCF : -5.28 (As of May. 09, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nymox Pharmaceutical's Enterprise Value is $23.30 Mil. Nymox Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.41 Mil. Therefore, Nymox Pharmaceutical's EV-to-FCF for today is -5.28.

The historical rank and industry rank for Nymox Pharmaceutical's EV-to-FCF or its related term are showing as below:

NYMXF' s EV-to-FCF Range Over the Past 10 Years
Min: -64.86   Med: -20.43   Max: -1.62
Current: -5.69

During the past 13 years, the highest EV-to-FCF of Nymox Pharmaceutical was -1.62. The lowest was -64.86. And the median was -20.43.

NYMXF's EV-to-FCF is ranked worse than
100% of 381 companies
in the Biotechnology industry
Industry Median: 6.23 vs NYMXF: -5.69

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-09), Nymox Pharmaceutical's stock price is $0.28025. Nymox Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.050. Therefore, Nymox Pharmaceutical's PE Ratio for today is At Loss.


Nymox Pharmaceutical EV-to-FCF Historical Data

The historical data trend for Nymox Pharmaceutical's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical EV-to-FCF Chart

Nymox Pharmaceutical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.80 -20.40 -18.92 -11.27 -5.39

Nymox Pharmaceutical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.70 -5.39 -15.35 -4.04 -11.08

Competitive Comparison of Nymox Pharmaceutical's EV-to-FCF

For the Biotechnology subindustry, Nymox Pharmaceutical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's EV-to-FCF falls into.



Nymox Pharmaceutical EV-to-FCF Calculation

Nymox Pharmaceutical's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=23.298/-4.412
=-5.28

Nymox Pharmaceutical's current Enterprise Value is $23.30 Mil.
Nymox Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nymox Pharmaceutical  (OTCPK:NYMXF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Nymox Pharmaceutical's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.28025/-0.050
=At Loss

Nymox Pharmaceutical's share price for today is $0.28025.
Nymox Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.050.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Nymox Pharmaceutical EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

Nymox Provides Current Update

By sperokesalga sperokesalga 05-10-2023

NYMOX Appeals Deficiency Letter

By Stock market mentor Stock market mentor 01-06-2023

NYMOX Appeals Deficiency Letter

By GlobeNewswire GlobeNewswire 01-06-2023

NYMOX Updates Shareholders

By PurpleRose PurpleRose 07-15-2022

NYMOX Receives RTF letter from FDA

By PurpleRose PurpleRose 07-12-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 05-23-2022

NYMOX Receives Deficiency Letter from NASDAQ

By PurpleRose PurpleRose 07-14-2022

NYMOX Announces New Marketing Submission for NYMOZARFEX� for BPH

By Value_Insider Value_Insider 12-05-2022

May 2023 Market Cap Requirement Update

By Value_Insider Value_Insider 11-25-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-22-2022